Amritsar Online

Becker Muscular Dystrophy Market Analysis of Epidemiology, Pipeline Therapies, and Key Companies Working in the market

 Breaking News
  • No posts were found

Becker Muscular Dystrophy Market Analysis of Epidemiology, Pipeline Therapies, and Key Companies Working in the market

October 04
20:42 2022
Becker Muscular Dystrophy Market Analysis of Epidemiology, Pipeline Therapies, and Key Companies Working in the market
Becker Muscular Dystrophy Market
DelveInsight’s “Becker Muscular Dystrophy Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Becker Muscular Dystrophy (BMD), historical and forecasted epidemiology as well as the Becker Muscular Dystrophy (BMD) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

DelveInsight’s “Becker Muscular Dystrophy  Market Insights, Epidemiology, and Market Forecast-2032 report delivers an in-depth understanding of the Becker Muscular Dystrophy (BMD), historical and forecasted epidemiology as well as the Becker Muscular Dystrophy (BMD) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

The Becker Muscular Dystrophy market report provides current treatment practices, emerging drugs, Becker Muscular Dystrophy (BMD) market share of the individual therapies, and current and forecasted Becker Muscular Dystrophy (BMD) market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current Becker Muscular Dystrophy (BMD) treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Becker Muscular Dystrophy market.

Some of the key facts of the Becker Muscular Dystrophy  Market Report

  • As per a study conducted by Romitti et al., which is titled “Prevalence of Duchenne and Becker Muscular Dystrophies in the United States”, the prevalence of BMD was 0.32 per 10 000 boys between the age group 5–9 years. However, the prevalence of BMD in males in the age group 5–24 years was estimated to be 0.30. This study also suggests that the prevalence of BMD is estimated to be 0.7–1.0 per 10,000 male individuals in North America, and 0.2–2.8 per 10,000 males in European countries.
  • As per a study conducted by Nakamura et al. titled “Characteristics of Japanese Duchenne and Becker muscular dystrophy patients in a novel Japanese national registry of muscular dystrophy (Remudy)”, by February 2012, 105 BMD patients were registered. Most individuals aged less than 20 years. In terms of genetic mutations of registrants of BMD, deletion of exons was the most frequent (61.4% and 79.0%) followed by point mutations (24.5% and 14.3%) and duplications (13.6% and 4.8%), respectively and  76.2% of BMD registrants were able to walk. 

Got queries? Click here to know more about the Becker Muscular Dystrophy Market Landscape

Becker Muscular Dystrophy Overview

Becker Muscular Dystrophy (BMD) is an inherited muscle structure disorder that results in progressive deterioration of limbs and cardiac and skeletal muscles. However, the involuntary muscles are not affected. BMD is a milder version of Duchenne Muscular Dystrophy (DMD). BMD usually begins in teens or early adulthood, and the course is slower and far less predictable than that of DMD. Early symptoms of BMD are cramps after exercising, and later in life, the person begins to experience problems while walking quickly or running. Other noticeable symptoms besides weakness are falling, feeling “worn out,” and changes in the skeletal system. Muscle weakness often affects the legs and pelvis, and slowly gets worse. Few affected individuals even have learning problems, but these cases are typically minor. 

 

BMD is caused due to a deformity of the DMD gene, which is an X-linked disorder (therefore, females are the carriers of this defect). This abnormality in the gene produces defective dystrophin protein. This protein helps stabilize and protect muscle fibers and may play a role in chemical signaling within cells. Muscle cells without fully functional dystrophin become damaged as muscles contract and relax with use. They then weaken and die over time, leading to muscle weakness and heart problems in people with BMD.

 

 

Becker Muscular Dystrophy Epidemiology Insights

 

  • According to the Genetic and Rare Diseases Information Center, the prevalence of BMD is estimated to be between 17–27 cases per million people. This means that at a given time, about one in 37,000 to one in 59,000 people are living with BMD. 
  • According to the Centers for Disease Control and Prevention (CDC), the estimated prevalence of Duchenne and Becker muscular dystrophy (DBMD) was one in every 7,250 males aged 5–24 years. However, the prevalence of DMD was found to be three times higher than the prevalence of BMD.

 

Becker Muscular Dystrophy Epidemiology Segmentation

 

  • Becker Muscular Dystrophy prevalent cases 
  • Becker Muscular Dystrophy treatable cases 
  • Becker Muscular Dystrophy diagnosed cases 
  • Becker Muscular Dystrophy age specific prevalent cases 

Becker Muscular Dystrophy   Market Outlook 

 

The Becker Muscular Dystrophy (BMD) market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Becker Muscular Dystrophy (BMD) market trends by analyzing the impact of current Becker Muscular Dystrophy (BMD) therapies on the market, unmet needs, drivers and barriers, and demand for better technology.

This segment gives a thorough detail of Becker Muscular Dystrophy (BMD) market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Becker Muscular Dystrophy (BMD) market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Becker Muscular Dystrophy (BMD) market in 7MM is expected to witness a major change in the study period 2019-2032.

Learn more by requesting for sample @Becker Muscular Dystrophy Market

Becker Muscular Dystrophy Key Companies

  • PTC Therapeutics
  • Italfarmaco
  • Epirium Bio
  • Edgewise Therapeutics
  • and many more 

 

Becker Muscular Dystrophy Therapies

  • Translarna
  • Givinostat
  • Epicatechin
  • EDG-5506 
  • and many more 

 

Table of Contents

  •  Key Insights 
  •  Report Introduction 
  •  Executive Summary of Becker Muscular Dystrophy   
  •  Disease Background and Overview
  •  Epidemiology and patient population
  •  The United States 
  •  EU 5
  •  Becker Muscular Dystrophy     Emerging Therapies
  • Becker Muscular Dystrophy   Market Outlook
  •  Market Access and Reimbursement of Therapies
  •  Appendix
  •  Becker Muscular Dystrophy   Report Methodology
  • DelveInsight Capabilities
  • Disclaimer

Click here to read more about Becker Muscular Dystrophy Market

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Related Articles